The phenotype of mice deficient in PTG suggests that the PTG gene is a candidate gene for type 2 diabetes and insulin resistance in humans. However, previous studies have indicated that PTG gene polymorphism does not contribute to insulin resistance or glucose intolerance (16, 17) . Given that G M gene polymorphism has been associated with insulin resistance in some human populations (18-20), it will be important to reexamine the possible relation between the PTG gene and insulin resistance in humans. 1 . Taylor, R., et al. 1996 . Direct assessment of liver glycogen storage by 13 C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects. (4, 5) . Taken together, these data suggest that CD4 + T cell production of IL-10 prevents the development of a CD4 + T cell-mediated, IL-12-driven, Th1-type inflammation in the intestine that is initiated by the presence of microbes in the gut lumen.
The mechanism(s) by which IL-10 signals inhibit immune cell activation is poorly understood. IL-10 binds to a recently described IL-10 receptor (IL-10R) complex that is composed of at least two subunits, IL-10Rα and IL-10Rβ -also known as CRFB4 or CRF2-4 (2). IL-10R signaling in macrophages requires the kinase Jak-1 and the transcription factor Stat3 (2). The essential role of Stat3 in mediating IL-10 signals in myeloid cells was demonstrated by the targeted deletion of Stat3 in myeloid cells (LysMCre/Stat3 flox-mice) that rendered neutrophils and macrophages unresponsive to IL-10 (6). This myeloid unresponsiveness to IL-10 resulted in the development of a polarized Th1-type immune response and chronic enterocolitis (6) . Thus, the specific inability of myeloid cells to respond to IL-10 through Stat3 signals appears to recapitulate spontaneous inflammation seen in IL-10 -/-mice. 
Cytokines and IBD in myeloid

LPS, TLR4, and IBD in myeloid Stat3-deficient mice
The first and perhaps critical step in initiating immune responses is typically the engagement of host Toll-like receptor (TLR) molecules by conserved pathogen associated molecular products (PAMPs) (10) . TLR ligation by PAMPs induces the activation of NF-κB and other transcription factors resulting in the production of multiple proinflammatory molecules. Recently, it has been appreciated that TLRs also influence the nature of the immune response, in particular T cell skewing toward a Th1 or Th2 profile. Myeloid cells, which are exquisitely sensitive to TLR ligands and produce significant IL-12p40, are therefore poised to play key roles in the initiation and possibly the Th1/Th2 skewing of inflammatory responses. The potency of myeloid cell TLR responses also warrants their effective negative regulation to prevent pathological inflammation. Kobayashi et al. (7) address the potential role of TLRs in the IL-12-driven IBD of The experimental evidence above and other data suggest that IL-10 might be a promising target for alleviating inflammation in human patients with IBD. Specifically, the evidence for the potential therapeutic use of IL-10 includes the fact that IL-10 suppresses the production of inflammatory cytokines by multiple immune cell types; continuous IL-10 treatment can prevent or ameliorate disease in several mouse models of IBD; IL-10 -/-mice develop IBD; and small trials of treatment with IL-10 in patients with ulcerative colitis showed reduced cytokine levels and improved histological scores (4, 11) . It is therefore vexing that recent clinical trials found no beneficial effect of IL-10 in the treatment of Crohn disease (12, 13) . It may be that the nature of the IBD being treated, the timing of IL-10 administration, the route of drug delivery, or the specific cell types being targeted by IL-10 will affect the outcome of the therapy (14) . Additionally, IL-10 may be more effective when used in consort with other novel or established treatments for IBD. It is clear that further experimental dissection, like that performed by Kobayashi et al. (7), of the cell types and/or factors that mediate the antiinflammatory effects of IL-10 in the intestinal mucosa are warranted.
